AI
By
Can Parallel Bio’s $21M Bet on Immune Organoids Cut Drug Failure Rates from 95% to 5%?
Key Highlights Organoid-AI Platform Aims to Transform Preclinical Drug DiscoveryParallel Bio’s proprietary platform replicates the human immune system…
Can BullFrog AI and Sygnature Discovery’s $30M Alliance Reshape How Global Biopharma Uses AI in Drug Discovery?
Key Highlights BullFrog AI Secures Global CRO Partner to Scale AI PlatformBullFrog AI has entered a commercial collaboration…
Can Receptor.AI’s Integration of REAXENSE™ Platform Redefine Full-Stack Drug Discovery?
Key Insights: Advanced Chemistry at ScaleReceptor.AI has incorporated the REAXENSE™ platform, developed by Canada-based Reaxense Inc., into its…
How Are NUS and UC San Diego Using AI to Unlock Sex-Specific Drug Combos for Aortic Valve Disease?
Key Highlights: AI-Powered Personalization: Unlocking Sex-Specific Drug EfficacyThe collaboration between the National University of Singapore’s WisDM and UC…
Biomni AI Agent Unveils New Era in Biology Research with Claude 4 Sonnet Integration and Extensive Toolset
A groundbreaking advancement in life sciences research has arrived with the launch of Biomni, a state-of-the-art AI agent…
Is NVIDIA’s 2025 Healthcare AI Report the Tipping Point for 80% of Providers and Pharma to Redefine Efficiency and Innovation?
Key Highlights Healthcare Sees Rapid ROI with Generative AIAccording to NVIDIA’s 2025 State of AI in Healthcare and…
